Business
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the quarter ended March 31, 2025, and provided a
About this update from Vyne Therapeutics Inc.
[{"type":"image","alt":"VYNE Therapeutics Inc.","displaySize":"","headline":null,"caption":"VYNE Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/0dff937be94d3584ccbd9cdc44c8d95c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FTNQA7Twe5TgVrsG.wz_xA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0dff937be94d3584ccbd9cdc44c8d95c","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Expected cash runway into 2H 2026","length":33,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":112,"olType":false},{"type":"text","content":"BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the quarter ended March 31, 2025, and provided a business update.","length":408,"tagName":"p"},{"type":"text","content":"“During the first quarter of 2025, we continued to progress our Phase 2b trial evaluating repibresib for the treatment of vitiligo, and we anticipate reporting top-line results from this trial mid-year,” said David Domzalski, President and Chief Executive Officer of VYNE. “With only one FDA-approved therapy, vitiligo remains an area of significant unmet need, and we believe repibresib has the potential to become a highly differentiated and important therapy for addressing this large patient population. With respect to VYN202, we will continue to work closely with the FDA to address the clinical hold placed on our Phase 1b psoriasis trial, and we expect to provide additional updates as we gain concurrence on the necessary steps needed to move forward and lift the clinical hold.”","length":788,"tagName":"p"},{"type":"text","content":"Recent Pipeline and Corporate Updates ","length":37,"tagName":"p"},{"type":"text","content":"Repibresib gel, a locally-administered small molecule pan-BD BET inhibitor (Phase 2b, nonsegmental vitil...